Novocure Ltd Ord Sh (NVCR)
$88.26 4.68 (5.04%)
19:56 EST NVCR Stock Quote Delayed 15 Minutes
Previous Close $88.26
Market Cap 7.46B
PE Ratio -
Volume (Avg. Vol.) 866,800
Day's Range 87.92 - 92.69
52-Week Range 41.51 - 98.84
Dividend & Yield N/A (N/A)
NVCR Stock Predictions, Articles, and Novocure Ltd Ord Sh News
- From InvestorPlace
- From the Web
August was a terrible time for stocks. September could be even worse. Here are 10 stocks to sell in the days ahead.
Medical device stocks could be the best play in all of healthcare. Here are five of the best choices for any portfolio.
These three pharma stocks all have the potential to deliver fantastic gains despite the industry’s turmoil.
This week, the ratings of 11 Health Care Equipment & Supplies stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
This week, the overall grades of 21 Health Care Equipment & Supplies stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
This week, the ratings of 7 Health Care Equipment & Supplies stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
From Market News Video
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Trinity Industries, Inc. (TRN), where a total volume of 4,865 contracts has been traded thus far today, a contract volume which is representative of approximately 486,500 underlying shares (given that every 1 contract represents 100 underlying shares)..
From Simply Wall St
The big shareholder groups in NovoCure Limited (NASDAQ:NVCR) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable<div><a class="permalink" href="https://simplywall.st/stocks/us/healthcare/nasdaq-nvcr/novocure/news/what-kind-of-investor-owns-most-of-novocure-limited-nasdaqnvcr/">Read More...</a></div>
From Talk Markets
Navellier RatingsPowered by Portfolio Grader